Ce nouvel agent thérapeutique, administré sous forme de gouttes ophtalmiques apporterait une commodité et une observance thérapeutiques très améliorées pour les patients atteints de la forme sèche -la ...
The shipment follows regulatory approvals for direct importation and positions AutoMax to begin marketing and sales activities for JAC Motors vehicles across Israel.
The company is a recipient of the Frost & Sullivan Global & APAC CRO Market Leadership & Customer Value Leadership Awards for the past five years. Avance Clinical provides services from pre-clinical ...
HealthEquity will discuss these results and estimates during a presentation by Scott Cutler, President and CEO, Steve Neeleman, Vice Chair and Founder and James Lucania, EVP and CFO, at the 43 rd ...
Jane Moen was appointed Vaso Corporation’s Chief Operating Officer. She will continue in her role as President of VasoHealthcare, a Vaso Corporation subsidiary. Ms. Moen has served as a Director of ...
The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects ...
VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...
NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the ATTENS trial, a double-blind randomized multicenter placebo-controlled trial of NeuroSigma’s Monarch® eTNS System ...
U.S. revenue between $158.2 - $158.4 million, representing ~21% growth ...
Wave received supportive initial feedback from FDA, who recognize the severity of HD and are receptive to and engaged with Wave regarding a potential pathway to accelerated approval. FDA is open to ...
More patients treated with ZTlido ® saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%). Of all study patients ...
NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...